Calydon Capital Trims Johnson & Johnson Stake

Investment firm reduces position in healthcare giant by 10.9%

Mar. 15, 2026 at 10:37am

Got story updates? Submit your updates here. ›

Calydon Capital, an investment management firm, has trimmed its position in Johnson & Johnson (NYSE: JNJ) by 10.9% in the third quarter, according to a recent SEC filing. The firm now owns 38,321 shares of the company's stock, down from 43,022 shares previously.

Why it matters

Johnson & Johnson is one of the world's largest and most diversified healthcare companies, with a portfolio spanning pharmaceuticals, medical devices, and consumer products. Changes in ownership by major institutional investors can provide insights into market sentiment and potential shifts in the stock's performance.

The details

According to the SEC filing, Calydon Capital sold 4,701 shares of Johnson & Johnson during the third quarter. The firm's total investment in JNJ is now valued at $7,106,000, accounting for 1.1% of its overall portfolio.

  • Calydon Capital trimmed its position in Johnson & Johnson in the 3rd quarter of 2026.

The players

Calydon Capital

An investment management firm that has reduced its stake in Johnson & Johnson.

Johnson & Johnson

A multinational healthcare company that develops, manufactures, and markets a broad range of products across pharmaceuticals, medical devices, and consumer health.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Calydon Capital's position in Johnson & Johnson may signal a shift in investor sentiment towards the healthcare giant, though the overall market remains bullish on the stock.